Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03

Treatments are limited after platinum Cetuximab or anti-PD1 failure for patients with recurrent/metastatic head and neck squamous cell carcinoma. Cabazitaxel has increased overall survival in hormone-refractory metastatic prostate cancer after failure of Docetaxel. Our aim was to detect a signal of...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Fayette, Jerome, Guigay, Joel, Tourneau, Christophe Le, Degardin, Marian, Peyrade, Frederic, Neidhardt, Eve-Marie, Sablin, Marie-Paule, Even, Caroline, Orlandini, Florence, Juzyna, Béata, Bellera, Carine
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2017
Pynciau:
Clinical Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5584293/
https://ncbi.nlm.nih.gov/pubmed/28881692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15901
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg